FDA Approves KarXT To Treat Schizophrenia; PureTech Health Gets $29 Mln Milestone Payment
This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb (BMS) in March of 2024. Royalty Pharma had acquired an interest in PureTech's royalty in KarXT.
Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...
In a phase II trial of moderate-to-severe major depressive disorder, 6 weeks of intensive treatment with psilocybin or ...
针对精神分裂症，目前所有获批上市的抗精神病药均为突触后多巴胺D2受体拮抗剂或部分激动剂，尤其是前者。这些药物为成千上万的患者带来了确切的获益，但也存在诸多局限性，如与D2受体阻断相关的不良反应，代谢副作用，针对某些症状维度疗效有限，以及部分患者治疗反 ...
Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...
Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. BMO Capital analyst notes ...
“KarXT是继20世纪50年代初第一代抗精神病药氯丙嗪诞生后，首款采用全新作用机制的抗精神病药物，两者相差70年左右。KarXT的获批有望为精神分裂症患者带来更多治疗选择。”9月27日，北京回龙观医院精神科主任医师陈松告诉人民日报健康客户端记者。
US poised to approve KarXT as new antipsychotic treatment for disorder, which could offer reduced side-effects ...
New revelations from the showdown between Novo Nordisk’s CEO and Bernie Sanders’ Senate health committee Tuesday; PhRMA’s legal victory in IRA case; the federal interest rate cut and anticipated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback